1. Home
  2. BBWI vs NAMS Comparison

BBWI vs NAMS Comparison

Compare BBWI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bath & Body Works Inc.

BBWI

Bath & Body Works Inc.

N/A

Current Price

$20.20

Market Cap

4.0B

ML Signal

N/A

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

N/A

Current Price

$30.60

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBWI
NAMS
Founded
1963
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.5B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
BBWI
NAMS
Price
$20.20
$30.60
Analyst Decision
Hold
Strong Buy
Analyst Count
16
8
Target Price
$25.61
$46.75
AVG Volume (30 Days)
5.1M
812.0K
Earning Date
06-02-2026
01-01-0001
Dividend Yield
3.91%
N/A
EPS Growth
N/A
N/A
EPS
1.17
N/A
Revenue
$7,307,000,000.00
N/A
Revenue This Year
N/A
$25.64
Revenue Next Year
$2.91
$530.85
P/E Ratio
$17.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.28
$14.06
52 Week High
$34.29
$42.00

Technical Indicators

Market Signals
Indicator
BBWI
NAMS
Relative Strength Index (RSI) 38.17 39.63
Support Level $19.15 $30.34
Resistance Level $20.36 $37.43
Average True Range (ATR) 1.17 1.72
MACD -0.37 -0.41
Stochastic Oscillator 2.47 20.05

Price Performance

Historical Comparison
BBWI
NAMS

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: